Hints and tips:
Related Topics
...A former Bausch & Lomb executive, the 49-year-old built Allergan through a succession of deals that began in 2013 when the company he ran, then called Actavis, bought Ireland-headquartered Warner Chilcott...
...In 2013 Ireland-based Warner Chilcott bought US-based Actavis, then in 2015, Actavis bought US-based Allergan....
...In 2013, US-based Actavis bought Ireland-headquartered Warner Chilcott, paving the way for the company to relocate its tax base away from the US and paved the way for a series of aggressive acquisitions...
...In 2013, US-based Actavis bought Ireland-headquartered Warner Chilcott, paving the way for the company to relocate its tax base away from the US and leading to aggressive acquisitions that culminated in...
...This helps explain how Actavis, Allergan’s predecessor, was able to reduce its tax rate to 17 per cent when it bought Warner Chilcott of Ireland in 2013....
...Among his recent transactions are Hertz’s spin off of its construction equipment rental business and Actavis’s acquisition of Warner Chilcott for $5bn....
...It bought Watson Pharmaceuticals for $6bn (2012), Ireland-domiciled Warner Chilcott for $9bn (2013) and Forest Laboratories for $25bn (2014)....
...Among companies that re-domiciled as Irish after “inversions” are Perrigo, which bought Elan, and Actavis, after its Warner Chilcott acquisition....
...Analysts said the Abbott deal would allow Mylan to compete on an equal footing with other generic drugmakers such as Actavis, which last year paid $5bn to buy Warner Chilcott, which is based in low-tax Ireland...
...Others to have made further deals after a successful inversion include Dublin-based Actavis, which followed its $5bn acquisition of Ireland’s Warner Chilcott in 2013 with the $25bn purchase of US rival Forest...
...That meant larger deals went more smoothly, such as the €4.5bn takeover of Actavis, which gave the company its new name, and the $8bn purchase of Warner Chilcott....
...Six months later he was back at the negotiating table, this time to buy Ireland’s Warner Chilcott for $8.5bn....
...Actavis’s Warner Chilcott deal (which moved its domicile to Ireland) is expected to take its tax rate from over 30 per cent down into the teens....
...Since then it has steadily grown by acquisition, including last year’s $8.5bn agreement to buy Ireland’s Warner Chilcott.”...
...Investors drew parallels with Actavis, the generic drugmaker, which last year fended off interest from companies including Valeant by acquiring Irish peer Warner Chilcott....
...Warner Chilcott has agreed to be bought by Actavis for $8.5bn. The deal lacks flash – both companies sell minor branded and generic drugs in women’s health, dermatology and the like....
...Warner Chilcott shareholders will receive 0.16 shares in Actavis for each share they own, equivalent to $20.08 per share....
...Actavis, the generic drugmaker, is in early discussions to buy Warner Chilcott, a pharmaceuticals company valued at more than $4.5bn....
...Since then it has steadily grown by acquisition, including last year’s $8.5bn agreement to buy Ireland’s Warner Chilcott....
...Consolidating deals within the sector have also included Actavis, which bought Warner Chilcott for $11bn and Valeant, which took over Bausch & Lomb for $8.7bn....
...Last year he acquired Ireland’s Warner Chilcott for $8.5bn. The $25bn purchase of Forest Laboratories, announced on Tuesday, is by far the largest transaction he has overseen so far....
...The Pfizer bid, which follows pharma groups such as Valeant and Actavis becoming Canadian and Irish companies respectively through mergers with Biovail and Warner Chilcott, is a stark illustration of the...
...Elsewhere, generic drugmaker Actavis climbed 1.3 per cent to $127.15 after it announced plans to acquire speciality pharmaceutical company Warner Chilcott for $5bn in stock....
...A few big deals are being done – Actavis buying Warner Chilcott, and Valeant purchasing Bausch & Lomb – but is this the start of another bout of industry consolidation or just more defensive moves?...
...Perhaps Warner Chilcott will get a fruit basket from Warburg Pincus. Last week, Warner, a maker of speciality pharmaceuticals, agreed to be acquired by generic drugmaker Actavis for $5bn....
International Edition